Evaluation of dermatological safety of investigational products by primary irritation patch test on healthy human volunteers of varied skin types
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- To evaluate the dermatological safety of the investigational products
研究概览
简要总结
Study Objective:The objective of this study is to evaluate thedermatological safety of the investigational products on healthy humansubjects.
Study Population: 24 healthy human volunteers (Male and Female1:1) with Skin types (Oily, Dry, Normal and Combination, 1:1:1:1 ratio).
Duration of study: Approximately 9 days for eachvolunteer.
Test Site: Between the scapula and waist of thesubjects, the test site should be free of pigmentation, pimple, hair, mole orany dermatological condition that can interfere with the reading.
This patch will then beapplied on the test site. The patch will be kept for 24 hours. After which thepatches will be removed and the first observation will be made at 30 minutes ofpatch removal (0 hr. observation). The further observations will be at 24 hrsand 1 week of patch removal
研究设计
- 研究类型
- Interventional
- 分配方式
- Not Applicable
- 盲法
- Not Applicable
入排标准
- 年龄范围
- 18.00 Year(s) 至 55.00 Year(s)（—）
- 性别
- All
入选标准
- •1.Subjects in age group
- •55 years (both the ages inclusive). 2.Healthy male & female subjects. 3.Subjects with Fitzpatrick skin type III to V. 4.Subjects willing to give a voluntary written informed consent. 5.Subjects willing to maintain the patch test in position for 24 hours. 6.Subject having not participated in a similar investigation in the past two weeks. 7.Subjects willing to come for regular follow up visits. 8.Subjects ready to follow instructions during the study period.
排除标准
- •1.Infection, allergy on the tested area.
- •2.Skin allergy, antecedents or atopic subjects.
- •3.Athletes and subjects with history of excessive sweating.
- •4.Cutaneous disease which may influence the study result.
- •5.Subjects on oral corticosteroid.
- •6.Subjects participating in any other cosmetic or therapeutic trial.
- •7.Any history of underlying uncontrolled medical illness including diabetes, liver disease or history of alcoholism, HIV or any other serious medical illness.
结局指标
主要结局
To evaluate the dermatological safety of the investigational products
时间窗: Approximately 9 days for each volunteer.
次要结局
未报告次要终点